Posted by Michael Wonder on 24 Nov 2016
USA’s BIO slams Japan’s pharma reimbursement and pricing system
23 November 2016 - The US trade group the Biotechnology Innovation Organization, has declared its disappointment in Japan's price modification of innovative drugs undermining predictable system.
The reaction comes in the wake of last’s week’s revelation that the Japanese government had slashed the price of the multi-indication cancer drug Opdivo (nivolumab) by half. US pharma major Opdivo, Bristol-Myers Squibb and Japanese drugmaker Ono Pharmaceuticals’ programmed death-1 immune checkpoint inhibitor is approved in Japan for treating advanced melanoma, non-small cell lung cancer and kidney cancer.
